Are Current Lipid Guidelines Adequate for South Asian Patients? A Narrative Review
By: Kavindya Fernando and Shamila De Silva
References
- Kalra D, Vijayaraghavan K, Sikand G, Desai NR, Joshi PH, Mehta A, et al. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: a clinical perspective from the National Lipid Association. J Clin Lipidol. 2021;15:402–422. DOI: 10.1016/j.jacl.2021.03.007
- Gupta K, Baloch F, Kakar TS, Agarwal H, Rawlley B, Khan UI, et al. The pandemic of coronary heart disease in South Asia: what clinicians need to know. Curr Atheroscler Rep. 2023;25:359–372. DOI: 10.1007/s11883-023-01110-5
- Gupta K, Al Rifai M, Hussain A, Minhas AMK, Patel J, Kalra D, et al. South Asian ethnicity: what can we do to make this risk enhancer a risk equivalent? Prog Cardiovasc Dis. 2022;75:21–32. DOI: 10.1016/j.pcad.2022.10.001
- Aayush P, Nair SJ, Chandni DP, Lekha AK, Natarajan P, Aravind JN, et al. Drivers of atherosclerotic cardiovascular disease in South Asians. JACC Asia. 2026. DOI: 10.1016/j.jacasi.2025.10.024
- Bilen O, Kamal A, Virani SS. Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: current state and future directions. World J Cardiol. 2016;8:247–257. DOI: 10.4330/wjc.v8.i3.247
- Ballantyne CM, Mark PB, Grundy SM, Hou JH, Tsai AS, Vaughan AB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. J Am Coll Cardiol. 2026;87:2624–2757. DOI: 10.1016/j.jacc.2025.11.016
- Correction to: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2023;148:
e5 . DOI: 10.1161/CIR.0000000000001172 - Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Guideline NG238. 2023. Available from:
https://www.nice.org.uk/guidance/ng238 (accessed 2 October 2026). - Puri R, Bansal M, Mehta V, Duell PB, Wong ND, Iyengar SS, et al. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus Statement IV. J Clin Lipidol. 2024;18:e351–e373. DOI: 10.1016/j.jacl.2024.01.006
- Nishant U, Patel PA, Bhatt DL, Natarajan P. South Asian representation in cardiovascular disease randomized controlled trials. JACC Asia. 2025;5:1244–1256. DOI: 10.1016/j.jacasi.2025.06.017
- McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–233. DOI: 10.1016/S0140-6736(08)61076-4
- Gujral UP, Kanaya AM. Epidemiology of diabetes among South Asians in the United States: lessons from the MASALA study. Ann N Y Acad Sci. 2021;1495:24–39. DOI: 10.1111/nyas.14530
- Karthikeyan G, Teo K, Islam S, McQueen M, Paris P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study. J Am Coll Cardiol. 2009;53:244–253. DOI: 10.1016/j.jacc.2008.09.041
- Sehayek D, Cole J, Björnson E, Wilkins JT, Mortensen MB, Dufresne L, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025;19:844–859. DOI: 10.1016/j.jacl.2025.05.024
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. DOI: 10.1093/eurheartj/ehz455
- Patel D, Koschinsky ML, Agarwala A, Natarajan P, Bhatia HS, Mehta A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease in South Asian individuals. J Am Heart Assoc. 2025;14:
e040361 . DOI: 10.1161/JAHA.124.040361 - Kar S. Elevated lipoprotein A in South Asians and the associated risk of cardiovascular disease: a systematic review. Curr Probl Cardiol. 2021;46:
100581 . DOI:10.1016/j.cpcardiol.2020.100581 - Makshood M, Joshi PH, Kanaya AM, Ayers C, Budoff M, Tsai MY, et al. Lipoprotein(a) and aortic valve calcium in South Asians compared to other race/ethnic groups. Atherosclerosis. 2020;313:14–19. DOI: 10.1016/j.atherosclerosis.2020.09.010
- Frishman WH, Mayo-Malasky P. Lipoprotein(a) testing and emerging therapies. Cardiol Rev. 2020;28:250–255. DOI: 10.1097/CRD.0000000000000295
- Chambers JC, Abbott J, Zhang W, Turro E, Scott WR, Tan S-T, et al. The South Asian genome. PLoS One. 2014;9:
e102645 . DOI: 10.1371/journal.pone.0102645 - Mettananda C, Fernando K, Solangaarachchige M, Premaratna R, Mallawa R, Fernando U, et al. Sex-related disparities in hyperlipidaemia and cardiovascular risk in Sri Lanka: a cross-sectional study. Lipids Health Dis. 2025;25:
13 . DOI: 10.1186/s12944-025-02812-2 - Setia N, Verma IC, Khan B, Arora A. Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population. Cardiol Res Pract. 2012;2012:
658526 . DOI: 10.1155/2012/658526 - Abraham N, Vijayakumar PP, Menon U, Bhavani N, Nair V, Futema M, et al. Whole exome sequencing and 12-SNP LDL polygenic score in South Indian patients with familial hypercholesterolemia. Sci Rep. 2026;16:
11474 . DOI: 10.1038/s41598-026-40367-z - Makshood M, Post WS, Kanaya AM. Lipids in South Asians: epidemiology and management. Curr Cardiovasc Risk Rep. 2019;13:
24 . DOI: 10.1007/s12170-019-0618-9 - Berry P, Amarchand R, Ramakrishnan L, Gupta R, Kondal D, Bharadiya V, et al. Establishing apolipoprotein-B and non-high-density-lipoprotein-C goals in Indian population: a cross-sectional study. Indian Heart J. 2024;76:154–158. DOI: 10.1016/j.ihj.2024.06.003
- Tillin T, Hughes AD, Whincup P, Mayet J, Sattar N, McKeigue PM, et al. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE). Heart. 2014;100:60–67. DOI: 10.1136/heartjnl-2013-304474
- Mantri NM, Merchant M, Rana JS, Go AS, Pursnani SK. Performance of the pooled cohort equation in South Asians: insights from a large integrated healthcare delivery system. BMC Cardiovasc Disord. 2022;22:
566 . DOI: 10.1186/s12872-022-02993-z - Parsons R, Liu X, Collister J, Clifton D, Cairns B, Clifton L. Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank. Heart. 2023;109:1690–1697. DOI: 10.1136/heartjnl-2022-321231
- SCORE2 Asia-Pacific writing group, Hageman SHJ, Huang Z, Lee H, Kaptoge S, Dorresteijn JAN, et al. Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model. Eur Heart J. 2025;46:702–715. DOI: 10.1093/eurheartj/ehae609
- Rungroj K. Cardiovascular risk prediction model in Asians. JACC Asia. 2024;4:275–278. DOI: 10.1016/j.jacasi.2024.01.007
- Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7:e1332–e1345. DOI: 10.1016/S2214-109X(19)30318-3
- Shah H, Garacci E, Behuria S, Cainzos-Achirica M, Kandula NR, Kanaya AM, et al. Cardiovascular risk-enhancing factors and coronary artery calcium in South Asian American adults: the MASALA study. Am J Prev Cardiol. 2023;13:
100453 . DOI: 10.1016/j.ajpc.2022.100453 - Al Rifai M, Kanaya AM, Kandula NR, Patel J, Al-Mallah MH, Budoff M, et al. Association of coronary artery calcium density and volume with predicted ASCVD risk and cardiometabolic risk factors in South Asians: the MASALA study. Curr Probl Cardiol. 2023;48:
101105 . DOI: 10.1016/j.cpcardiol.2022.101105 - Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
- Singh K, Thanassoulis G, Dufresne L, Nguyen A, Gupta R, Narayan KMV, et al. A comparison of lipids and apoB in Asian Indians and Americans. Glob Heart. 2021;16:
9 . DOI: 10.5334/gh.882 - Quispe R, Michos ED, Martin SS, Puri R, Toth PP, Al Suwaidi J, et al. High-sensitivity C-reactive protein discordance with atherogenic lipid measures and incidence of ASCVD in primary prevention: the ARIC study. J Am Heart Assoc. 2020;9:
e013600 . DOI: 10.1161/JAHA.119.013600 - Adejumo FA, Obielodan OO, Egwu EO, Oyedele TJ, Fasanye EH, Niyi-Oriolowo E, et al. Polygenic risk scores for cardiovascular disease: clinical utility and limitations. Egypt Heart J. 2026;78:
34 . DOI: 10.1186/s43044-026-00746-3 - Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46:4359–4378. DOI: 10.1093/eurheartj/ehaf190
- World Health Organization. WHO updates guidelines on fats and carbohydrates. Geneva: WHO; 2023. Available from:
https://www.who.int/news/item/17-07-2023-who-updates-guidelines-on-fats-and-carbohydrates (accessed 2 October 2026). - Misra A, Sharma R, Gulati S, Joshi SR, Sharma V, Ghafoorunissa, et al. Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians. Diabetes Technol Ther. 2011;13:683–694. DOI: 10.1089/dia.2010.0198
- Food Safety and Standards Authority of India. Food Safety and Standards (Prohibition and Restrictions on Sales) Second Amendment Regulations, 2021. New Delhi: FSSAI; 2021. Available from:
https://fssai.gov.in/food-law/regulations (accessed 2 October 2026). - Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–341. DOI: 10.1016/j.clpt.2005.06.013
- Yang J, Li LJ, Wang K, He YC, Sheng YC, Xu L, et al. Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients. Acta Pharmacol Sin. 2011;32:116–125. DOI: 10.1038/aps.2010.169
- U.S. Food and Drug Administration. Crestor (rosuvastatin calcium) tablets, prescribing information. Silver Spring, MD: FDA; 2016. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021366s043s044lbl.pdf (accessed 2 October 2026). - Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol. 2007;99:1538–1543. DOI: 10.1016/j.amjcard.2007.01.028
DOI: https://doi.org/10.5334/gh.1590 | Journal eISSN: 2211-8179
Language: English
Page range: 72 - 72
Submitted on: Jul 12, 2026
Accepted on: Sep 25, 2026
Published on: Oct 8, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Keywords:
© 2026 Kavindya Fernando, Shamila De Silva, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.